The SGLT2i drugs promote the loss of glucose in the urine, which can impact the mTOR signalling pathway and modulate AMPK activity; and both molecular pathways play a role in cerebral amyloid deposition and development of Alzheimer’s disease [14]. This evidence concerns the gene MTOR and early-onset autosomal dominant Alzheimer disease.